Skip to main content
Almirall S.A. logo

Almirall S.A. — Investor Relations & Filings

Ticker · ALM ISIN · ES0157097017 LEI · 95980020140005007996 MC Manufacturing
Open in API
Filings indexed 284 across all filing types
Latest filing 2022-03-30 Investor Presentation
Country ES Spain
Listing MC ALM

About Almirall S.A.

http://www.almirall.com

Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.

Recent filings

Filing Released Lang Actions
Presentación datos de 16 semanas para los estudios fase 3 ADvocate 1 y 2 de Lebrikizumab: Encuentro con Analistas e Inversores Institucionales
Investor Presentation Classification · 98% confidence The document is a presentation dated March 30, 2022, announcing and detailing the 16-week Phase 3 study data (ADvocate 1 and 2) for the drug Lebrikizumab. The text explicitly states: 'Mantendrá un webcast con analistas e inversores institucionales acerca de los datos de 16 semanas...' and 'Adjuntamos la presentación.' The content is a detailed slide deck covering mechanism of action, market potential, study design, and efficacy results (EASI-75, IGA). This structure—a formal presentation provided to investors/analysts regarding clinical trial data—is characteristic of an Investor Presentation (IP). It is not a full regulatory report (10-K, IR), an earnings release (ER), or a simple announcement of a report (RPA), as the presentation itself is the primary content being delivered to investors.
2022-03-30 Spanish
Los datos de 16 semanas para los estudios fase 3 ADvocate 1 y 2 de Lebrikizumab se han anunciado hoy en el congreso anual de la American Academy of Dermatology (AAD)
Regulatory Filings Classification · 95% confidence The document is a press release from Almirall, S.A., dated March 26, 2022, announcing clinical trial data (ADvocate 1 and 2 studies for Lebrikizumab) presented at the American Academy of Dermatology (AAD) annual congress. It details efficacy and safety results, mentions future regulatory filings, and concludes with the statement, "A continuación adjuntamos la nota de prensa." (Attached below is the press release.) This structure—a formal announcement of results, often referencing a presentation or a regulatory update, and explicitly stating the press release is attached/included—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of periodic financial/clinical results (Phase 3 trial data presentation), it fits best under the Earnings Release (ER) category, which covers initial announcements of periodical results (even if clinical/pipeline updates are often included in ERs or investor presentations). However, the text is very detailed, resembling an Investor Presentation (IP) or Management Discussion & Analysis (MDA) in depth, but it is framed as a formal regulatory disclosure ("en cumplimiento de lo dispuesto en la Ley del Mercado de Valores") about data presented at a conference. Given the options, 'ER' (Earnings Release) is the closest fit for a major periodic announcement of clinical/business progress, although 'IP' (Investor Presentation) is also plausible if this were the presentation itself. Since it reads like a formal news release summarizing key findings, ER is selected. It is not a short RPA because it contains substantial detail, not just a pointer to another document.
2022-03-26 Spanish
Presidente del Consejo de Administración
Board/Management Information Classification · 99% confidence The document is a short announcement dated February 21, 2022, titled 'INFORMACIÓN PRIVILEGIADA' (Inside Information). It explicitly states that a member of the Board of Directors, Don Jorge Gallardo Ballart, intends to resign as Chairman of the Board, and the Board has decided to appoint a successor, Don Carlos Gallardo Piqué. This content directly relates to changes in the company's senior management and board structure. This aligns perfectly with the definition for Board/Management Information (MANG). The document length is very short (950 chars), but it contains the substantive announcement itself, not just a notice that a report is attached, thus ruling out RPA/RNS based on the 'MENU VS MEAL' rule.
2022-02-21 Spanish
Convocatoria de la Junta General Ordinaria de Accionistas de la Sociedad
AGM Information Classification · 98% confidence The document explicitly announces the convocation of the 'Junta General Ordinaria de Accionistas' (Ordinary General Shareholders' Meeting) scheduled for May 6, 2022. The text details the agenda ('Orden del día'), which includes voting on annual accounts, capital increases, dividend distribution, and remuneration reports. This content is characteristic of materials prepared for an Annual General Meeting (AGM). Although it mentions that related documents (annual accounts, remuneration report, corporate governance report) will be communicated separately, the primary purpose of this filing is the official notice and details of the AGM itself. Therefore, the most appropriate classification is AGM Information (AGM-R).
2022-02-21 Spanish
Corporate Governance Report - Almirall S.A.
Remuneration Information Classification · 99% confidence The document text is highly detailed, focusing exclusively on the remuneration policy for the Board of Directors and senior management (Consejero Delegado) of ALMIRALL, S.A. It discusses fixed salaries, variable bonuses (annual and multi-year plans like SEUs and Long Term Company Performance Plan), benefits in kind, and the structure for determining these payments. This content directly corresponds to the disclosure requirements for executive and director compensation. The specific section headers like 'A. POLÍTICA DE REMUNERACIONES DE LA SOCIEDAD PARA EL EJERCICIO EN CURSO' and detailed breakdowns of compensation components strongly indicate this is a Remuneration Report. In the provided list, 'Remuneration Information (Code: DEF 14A)' is the closest match, as DEF 14A filings in the US context cover executive compensation disclosures, which aligns with the detailed nature of this Spanish regulatory disclosure on remuneration policy.
2022-02-21 Spanish
Corporate Governance Report - Almirall S.A.
Governance Information Classification · 98% confidence The document text is structured around 'DATOS IDENTIFICATIVOS DEL EMISOR' (Issuer Identification Data), 'ESTRUCTURA DE LA PROPIEDAD' (Ownership Structure), detailing capital, voting rights, significant shareholders (titulares de participaciones significativas), and relationships between directors and major shareholders. It specifically references the 'fecha fin del ejercicio de referencia: 31/12/2021' and reports on ownership changes during the year. This content is characteristic of a mandatory annual disclosure regarding corporate governance and ownership structure, which aligns closely with the requirements for an Annual Report (10-K) or a specific governance/ownership filing. Given the focus solely on ownership structure, significant shareholdings, and director relationships, it strongly suggests a filing related to shareholder structure disclosure, which is often a component of the Annual Report (10-K) or a specific governance report. However, the structure strongly resembles the mandatory disclosures required in Spanish regulatory filings concerning significant shareholdings and board representation, which are often consolidated in the Annual Report or a dedicated governance filing. Since the document details the ownership structure as of the year-end (31/12/2021) and includes detailed tables on significant shareholders and board representation linked to those shareholders, it is most likely a component or extract from the Annual Report (10-K) or a specific governance report. Given the options, the detailed ownership and governance structure reporting points towards the comprehensive nature of the Annual Report (10-K) or Governance Information (CGR). Since it is a detailed report structure rather than a brief announcement, and covers the full fiscal year end, 10-K is a strong candidate, but CGR (Governance Information) is also highly relevant for this specific content. Comparing the content to the definitions, it is a detailed report on ownership and governance structure, not just a brief factsheet (FS) or a simple announcement (RPA/RNS). Because it covers the entire ownership structure at year-end, it is best classified as part of the comprehensive Annual Report (10-K) or Governance Information (CGR). Given the depth of ownership disclosure, 10-K is often the container for this level of detail, but CGR specifically covers 'internal rules, board structure, and governance practices'. Since the document is heavily focused on ownership structure and director links (A.1 through A.7), CGR is a very precise fit for this specific section's content, even if it is extracted from a larger 10-K. I will select CGR as the most precise fit for the detailed governance/ownership structure presented.
2022-02-21 Spanish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.